Company Overview of EpiVax, Inc.
EpiVax, Inc. is a biotechnology company that engages in the development and implementation of computational immunology tools. It provides interactive protein screening and reengineering interface for Web-based immunogenicity screening; and pre-deimmunization of a functional therapeutic report that is a concise description of a protein therapeutic candidate’s immunogenic potential. The company also offers EpiMatrix high throughput antibody immunogenicity prediction report that gives an overall assessment of potential clinical immunogenicity for a large set of antibody candidates; and Chinese hamster ovary protein predicted immunogenicity, an informatics tool to assess the immunogenic risk of ...
146 Clifford Street
Providence, RI 02903
Founded in 1998
Key Executives for EpiVax, Inc.
Founder, Chief Executive Officer and Chief Scientific Officer
Chief Operating Officer and Chief Information Officer
Head of Marketing and Business Development
Director of Molecular Immunology
Compensation as of Fiscal Year 2014.
EpiVax, Inc. Key Developments
EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
EpiVax, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
EpiVax, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
EpiVax, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Biotest AG and EpiVax, Inc. Announce Collaborative Research Agreement
Dec 3 13
Biotest AG and EpiVax, Inc. announced a new collaborative research agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by developing inhibitory antibodies. The formation of inhibitory antibodies against the Coagulation factor VIII reduces its efficacy and may lead to severe bleeding disorders. Immunogenicity suppression will be also achieved through integration of EpiVax' proprietary Tregitope, an immune-modulating technology, with the FVIII treatment. A tolerized and de-immunized version of factor VIII would allow patients and their families to experience the benefits of FVIII treatment, which does not induce a reaction of the immune system (no immunogenicity) without the fear of developing inhibitory antibodies ('inhibitors') against the therapeutic factor VIII. Studies carried out by EpiVax and collaborators indicate that Tregitope may be useful for reducing the antibody formation (inducing tolerance) to transplants, protein drugs, and allergens by 'Tregitopes'.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries